Exclusive Summary

• As a WHO Essential Medicine and the undisputed first-line 'gold standard' for bipolar disorder, the global base of ~40 million patients guarantees highly stable, lifelong demand.
• The 300mg sustained-release formulation smooths serum concentration peaks, substantially reducing GI and neurological side effects, driving strong clinical preference over immediate-release tablets.
• With all originator patents fully expired and recent widespread lithium supply shortages repeatedly reported across multiple Western countries, a perfect, risk-free window exists for rapid market entry.
• Leveraging China's mature pharmaceutical manufacturing capabilities, the product offers assured high-quality supply at a highly aggressive cost, ensuring lucrative margins for overseas distributors.